DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering

DSS (NYSE American: DSS) closed a firm commitment underwritten public offering, generating approximately $1.0 million in gross proceeds from the sale of 900,000 shares of common stock at $1.00 per share.

Rhea-AI Summary

DSS (NYSE American: DSS) closed a firm commitment underwritten public offering, generating approximately $1.0 million in gross proceeds from the sale of 900,000 shares of common stock at $1.00 per share. An underwriter overallotment option covers up to 135,000 additional shares (15%). Net proceeds are expected to be used for general corporate purposes, including working capital. The offering was made under an effective Form S-3 (No. 333-281974) declared effective November 5, 2024, and Aegis Capital Corp. acted as book-running manager.

Argus Feb 5 session

-5.31% close to close Open Argus

Details

News Market Reaction – DSS

On Feb 5, the day this news came out, DSS closed 5.31% below the previous close.

Data tracked by StockTitan Argus for the Feb 5 session.

Market Context

On Feb 5, the day this news came out, the stock closed 5.3% below the previous close. The decline re...

Analysis

On Feb 5, the day this news came out, the stock closed 5.3% below the previous close. The decline reflects ongoing dilution concerns after DSS closed its $1.0 million underwritten offering of 900,000 shares at $1.00. A prior pricing release already coincided with a -32.37% move, and the historical average move for offering-tagged news of -7.28% shows that capital raises have often pressured the stock, underscoring sensitivity to balance sheet and funding actions.

Key Figures

Gross proceeds: $1.0 million Offering size: 900,000 shares Offering price: $1.00 per share +5 more

Gross proceeds

$1.0 million

Underwritten public offering gross proceeds before fees

Offering size

900,000 shares

Shares of common stock sold in the offering

Offering price

$1.00 per share

Public offering price of common stock

Overallotment shares

135,000 shares

Additional shares available under overallotment option (15%)

Overallotment percentage

15%

Portion of base offering size subject to overallotment

Registration number

333-281974

Form S-3 shelf registration statement reference

Shelf filing date

October 31, 2024

Date Form S-3 filed with SEC as cited in release

Effectiveness date

November 5, 2024

Date Form S-3 declared effective by SEC

Previous Offering Reports

2 past events · Latest: Feb 04

Same Type 2 events

1. Feb 04

   Offering priced

   24h Move

   -32.4%

   Pricing of 900,000-share underwritten public offering at $1.00 per share.

2. Feb 03

   Offering launched

   24h Move

   +17.8%

   Announcement of proposed public offering for general corporate and working capital.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

firm commitment underwritten public offering, overallotment option, shelf registration statement, form s-3, +1 more

5 terms

firm commitment underwritten public offering financial

"announced the closing of its previously announced firm commitment underwritten public offering."

A firm commitment underwritten public offering is when an investment bank agrees to buy all new shares from a company at an agreed price and then resell them to investors, taking on the risk that it must sell the stock. Think of it like a retailer buying a full shipment up front so the seller is guaranteed cash. For investors, it guarantees the company will raise a specific amount but can dilute existing shareholders and affect market price depending on how the resale goes.

overallotment option financial

"granted Aegis Capital Corp., the underwriter, an overallotment option to purchase"

An overallotment option (often called a "greenshoe") is a pre-arranged allowance for underwriters to sell or buy up to a specified extra percentage of a company’s shares during an offering to meet unexpected demand or support the share price. Think of it as a short-term buffer: it helps reduce wild swings right after shares start trading but can slightly increase the total shares outstanding if the option is exercised, which matters to investors because it affects supply, price stability, and potential dilution.

shelf registration statement regulatory

"The offering was made pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"effective shelf registration statement on Form S-3 (No. 333-281974) previously filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company.

The offering consisted of 900,000 shares of common stock. The public offering price per share of common stock was $1.00. In addition, the Company granted Aegis Capital Corp., the underwriter, an overallotment option to purchase up to an additional 135,000 shares of common stock, representing 15% of the number of shares sold in the offering solely to cover over-allotments, if any.

The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital.

Aegis Capital Corp. acted as the sole book-running manager for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.

The offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281974) previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, and declared effective by the SEC on November 5, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About DSS, Inc.

DSS, Inc. (NYSE American: DSS) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

For investor and media inquiries or additional information, please contact:

Investor Contact:

DSS, Inc.
Investor Relations
ir@dssworld.com
+1 (585) 565-2422

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did DSS (DSS) raise in the February 5, 2026 public offering?

DSS raised approximately $1.0 million in gross proceeds from the offering. According to the company, the sale consisted of 900,000 shares at $1.00 per share, before underwriting fees and offering expenses.

What was the share count and price in DSS's (DSS) February 2026 offering?

The offering sold 900,000 shares of common stock at $1.00 per share. According to the company, the underwriter also received an overallotment option for up to 135,000 additional shares (15%).

Who managed the DSS (DSS) underwritten public offering and who were the counsels?

Aegis Capital Corp. acted as the sole book-running manager for the offering. According to the company, Sichenzia Ross Ference Carmel LLP advised DSS and Kaufman & Canoles advised Aegis Capital.

What will DSS (DSS) use the net proceeds from the offering for?

DSS expects to use net proceeds for general corporate purposes, including working capital. According to the company, no specific projects or allocations were disclosed in the announcement.

Where can investors find the final prospectus for DSS's (DSS) offering?

The final prospectus supplement and accompanying prospectus will be filed with the SEC and available at www.sec.gov. According to the company, electronic copies can also be requested from Aegis Capital's syndicate department.